Salute, le Car T ide-cel, liso-cel ora rimborsabili per mieloma multiplo e linfoma diffuso a grandi cellule B

adnkronos

(Adnkronos) - Nuove speranze per pazienti con malattia oncoematologica. Con una conferenza stampa a Roma Bristol Myers Squibb ha annunciato il via libera dell’Agenzia italiana del farmaco alla rimborsabilità di due terapie cellulari Car T. La prima è idecabtagene vicleucel (ide-cel), indicata nel trattamento del mieloma multiplo. La seconda è lisocabtagene maraleucel indicata per il linfoma diffuso a grandi cellule B, per il linfoma primitivo del mediastino a grandi cellule B e per il linfoma follicolare di grado 3B in recidiva o refrattari al trattamento dopo due o più linee di terapia sistemica.

Transcript

00:00The Italian Pharmaceutical Agency has given way to the reimbursability of two cell therapies

00:09with CAR-T, Ide-Cell for the treatment of multiple myeloma and Iso-Cell for lymphoma

00:13spread to large cells B. The therapies are suitable for adult patients

00:17with recurrent and refractory disease who have already received at least three previous

00:22therapies.

00:23Ide-Cell for the treatment of multiple myeloma and Iso-Cell for lymphoma spread to large

00:30cells B. The therapies are suitable for adult patients

00:33with recurrent and refractory disease who have already received at least three previous

00:38therapies.

00:39Ide-Cell for the treatment of multiple myeloma and Iso-Cell for lymphoma spread to large

00:43cells B. The therapies are suitable for adult patients

00:46with recurrent and refractory disease who have already received at least three previous

00:51therapies.

00:52Ide-Cell today represents the only therapeutic option for patients affected by multiple myeloma

00:57who have not responded to the three first-line therapies, which have shown refractoryness

01:01to the last line of therapy and which, in the absence of treatment with Ide-Cell, would

01:05have a survival expectancy of less than a year.

01:08Having at our disposal a therapy that exceeds the resistance mechanisms, which is able to

01:16offer responses in about 80% of a population of patients who have used any other therapeutic

01:24alternative and to offer a survival expectancy of about two years with a good quality of

01:31life, because the therapy we are talking about is a therapy with a single infusion and

01:39it certainly represents a great success, but above all a great therapeutic possibility

01:46that can be offered to our patients.

01:49The new cases of lymphoma in Italy are more than 14,000 every year and the first line of

01:54treatment cures over 50% of patients. For those who, on the other hand, do not respond

01:59to the first-line therapy and are affected by the most aggressive forms of lymphoma,

02:04such as the primary form of mediastinum and the follicular form of grade 3, today LISO

02:08represents a potentially curative treatment.

02:11The revolution is precisely in this, this group of patients for whom we had extremely

02:18limited therapeutic prospects, with an almost absence of probability of healing, today

02:25they are able to obtain certainly amazing results.

02:29If we look, for example, at the study that has been done with LISO-Cell, we can see how

02:39the percentage of complete and partial remissions rises by 75%, but above all there are more

02:49than 50% of patients who obtain a complete remission. Many of these complete remissions

02:55remain permanent, thus giving the idea of a definitive healing.

Category

Transcript

Recommended